Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cempra, Inc. (CEMP) PT Lowered to $4 at Stifel; Reiterates Hold
March 1, 2017 8:59 AM ESTStifel lowered its price target on Cempra, Inc. (NASDAQ: CEMP) to $4.00 (from $8.00) while maintaining a Hold rating. GAAP net loss of $31.5M, or $(0.60)/share, was wider than Consensus' $(0.55) estimates.
Analyst Stephen Willey commented, "Incremental solithromycin updates provided on managements 4Q16 earnings announcement/call... More
Cempra (CEMP) Underperform Rating Reiterated at Baird Post Q4
February 28, 2017 12:45 PM ESTJefferies analyst Brian Skorney reiterated his Underperform rating and $2 price target on Cempra, Inc. (NASDAQ: CEMP) following results.
Skorney commented, "Cempra reported in-line earnings in 4Q16, along with a host of trial discontinuations, failure in gonorrhea, and updates on discussions with... More
Cempra (CEMP) Misses Q4 EPS by 1c, to Reduce Workforce
February 28, 2017 6:52 AM ESTCempra (NASDAQ: CEMP) reported Q4 EPS of ($0.60), $0.01 worse than the analyst estimate of ($0.59).
Corporate Restructuring Action
As a consequence of the CRL we received, and subsequent discussions with the FDA, resulting in a delay of the potential approval of solithromycin, we recently... More
